|
1
|
Tilly H, da Silva Gomes M, Vitolo U, Jack
A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW,
Pfreundschuh M, et al: Diffuse large B-cell lymphoma: ESMO clinical
practice guidelines, treatment and follow-up. Ann Oncol. 26 Suppl
5:v116–v125. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
International non-Hodgkin's lymphoma
prognostic factors project: A predictive model for aggressive
non-Hodgkin's lymphoma. N Engl J Med. 329:987–994. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ziepert M, Hasenclever D, Kuhnt E, Glass
B, Schmitz N, Pfreundschuh M and Loeffler M: Standard International
prognostic index remains a valid predictor of outcome for patients
with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin
Oncol. 28:2373–2380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ngo L, Hee SW, Lim LC, Tao M, Quek R, Yap
SP, Loong EL, Sng I, Hwan-Cheong TL, Ang MK, et al: Prognostic
factors in patients with diffuse large B cell lymphoma: Before and
after the introduction of rituximab. Leuk Lymphoma. 49:462–469.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sehn LH, Berry B, Chhanabhai M, Fitzgerald
C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J,
et al: The revised international prognostic index (R-IPI) is a
better predictor of outcome than the standard IPI for patients with
diffuse large B-cell lymphoma treated with R-CHOP. Blood.
109:1857–1861. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alizadeh AA, Eisen MB, Davis RE, Ma C,
Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al:
Distinct types of diffuse large B-cell lymphoma identified by gene
expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Choi WW, Weisenburger DD, Greiner TC,
Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz
G, et al: A new immunostain algorithm classifies diffuse large
B-cell lymphoma into molecular subtypes with high accuracy. Clin
Cancer Res. 15:5494–5502. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meyer PN, Fu K, Greiner TC, Smith LM,
Delabie J, Gascoyne RD, Ott G, Rosenwald A, Braziel RM, Campo E, et
al: Immunohistochemical methods for predicting cell of origin and
survival in patients with diffuse large B-Cell lymphoma treated
with rituximab. J Clin Oncol. 29:200–207. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Swerdlow SH, Campo E, Pileri SA, Harris
NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz
AD and Jaffe ES: The 2016 revision of the World Health Organization
classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Molina TJ, Canioni D, Copie-Bergman C,
Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC,
Casasnovas O, et al: Young patients with non-germinal center
B-cell-like diffuse large B-cell lymphoma benefit from intensified
chemotherapy with ACVBP plus rituximab compared with CHOP plus
rituximab: Analysis of data from the groupe d'Etudes des lymphomes
de l'Adulte/lymphoma study association phase III trial LNH 03-2B. J
Clin Oncol. 32:3996–4003. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ruan J, Martin P, Furman RR, Lee SM,
Cheung K, Vose JM, Lacasce A, Morrison J, Elstrom R, Ely S, et al:
Bortezomib plus CHOP-rituximab for previously untreated diffuse
large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol.
29:690–697. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nowakowski GS, LaPlant B, Macon WR, Reeder
CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ,
Micallef IN, et al: Lenalidomide combined with R-CHOP overcomes
negative prognostic impact of non-germinal center B-cell phenotype
in newly diagnosed diffuse large B-Cell lymphoma: A phase II study.
J Clin Oncol. 33:251–257. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Younes A, Thieblemont C, Morschhauser F,
Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J,
Bandyopadhyay N, et al: Combination of ibrutinib with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)
for treatment-naive patients with CD20-positive B-cell non-Hodgkin
lymphoma: A non-randomised, phase 1b study. Lancet Oncol.
15:1019–1026. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheson BD, Fisher RI, Barrington SF,
Cavalli F, Schwartz LH, Zucca E and Lister TA: Alliance,
Australasian Leukaemia and Lymphoma Group; Eastern Cooperative
Oncology Group: Recommendations for initial evaluation, staging,
and response assessment of Hodgkin and non-Hodgkin lymphoma: The
Lugano classification. J Clin Oncol. 32:3059–3068. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Prevodnik VK, Lavrenčak J, Horvat M and
Novakovič BJ: The predictive significance of CD20 expression in
B-cell lymphomas. Diagn Pathol. 6:332011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schwartz A, Gaigalas AK, Wang L, Marti GE,
Vogt RF and Fernandez-Repollet E: Formalization of the MESF unit of
fluorescence intensity. Cytometry B Clin Cytom. 57:1–6. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Benesova K, Forsterova K, Votavova H,
Campr V, Stritesky J, Velenska Z, Prochazka B, Pytlik R and Trneny
M: The Hans algorithm failed to predict outcome in patients with
diffuse large B-cell lymphoma treated with rituximab. Neoplasma.
60:68–73. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kumar A, Lunning MA, Zhang Z, Migliacci
JC, Moskowitz CH and Zelenetz AD: Excellent outcomes and lack of
prognostic impact of cell of origin for localized diffuse large
B-cell lymphoma in the rituximab era. Br J Haematol. 171:776–783.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Salles G, de Jong D, Xie W, Rosenwald A,
Chhanabhai M, Gaulard P, Klapper W, Calaminici M, Sander B, Thorns
C, et al: Prognostic significance of immunohistochemical biomarkers
in diffuse large B-cell lymphoma: A study from the lunenburg
lymphoma biomarker consortium. Blood. 117:7070–7078. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Castillo JJ, Beltran BE, Song MK, Ilic I,
Leppa S, Nurmi H, Seki R, Uccella S, Li JM, Treaba DO, et al: The
Hans algorithm is not prognostic in patients with diffuse large
B-cell lymphoma treated with R-CHOP. Leuk Res. 36:413–417. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Johnson NA, Boyle M, Bashashati A, Leach
S, Brooks-Wilson A, Sehn LH, Chhanabhai M, Brinkman RR, Connors JM,
Weng AP and Gascoyne RD: Diffuse large B-cell lymphoma: Reduced
CD20 expression is associated with inferior survival. Blood.
113:3773–3780. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fu K, Weisenburger DD, Choi WW, Perry KD,
Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, et al:
Addition of rituximab to standard chemotherapy improves the
survival of both the germinal center B-cell-like and non-germinal
center B-cell-like subtypes of diffuse large B-cell lymphoma. J
Clin Oncol. 26:4587–4594. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yoon DH, Choi DR, Ahn HJ, Kim S, Lee DH,
Kim SW, Park BH, Yoon SO, Huh J, Lee SW and Suh C: Ki-67 expression
as a prognostic factor in diffuse large B-cell lymphoma patients
treated with rituximab plus CHOP. Eur J Haematol. 85:149–157.
2010.PubMed/NCBI
|
|
25
|
He X, Chen Z, Fu T, Jin X, Yu T, Liang Y,
Zhao X and Huang L: Ki-67 is a valuable prognostic predictor of
lymphoma but its utility varies in lymphoma subtypes: Evidence from
a systematic meta-analysis. BMC Cancer. 14:1532014. View Article : Google Scholar : PubMed/NCBI
|
